In addition to HER2-driven cancers, preclinical data suggest that NRG1-driven cancers, which include a significant proportion of squamous cell carcinomas of the head and neck (SCCHN), are also likely to benefit from HER3-directed therapy [13, 14]. Here, ERBB3 is linked to cancer.